Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Celcuity (CELC) Stock Price

Headlines about Celcuity (NASDAQ:CELC) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celcuity earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.5681637225251 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Celcuity (NASDAQ CELC) traded up $0.17 during trading hours on Friday, hitting $19.05. 8,519 shares of the stock traded hands, compared to its average volume of 42,657. The firm has a market cap of $193.79 and a PE ratio of -29.31. Celcuity has a one year low of $11.10 and a one year high of $21.98.

Separately, Craig Hallum initiated coverage on shares of Celcuity in a research report on Monday, October 16th. They issued a “buy” rating for the company.

In related news, Director Richard Nigon purchased 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The shares were bought at an average cost of $17.48 per share, with a total value of $131,100.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

COPYRIGHT VIOLATION WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at

About Celcuity

Celcuity, Inc is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it.

Insider Buying and Selling by Quarter for Celcuity (NASDAQ:CELC)

What are top analysts saying about Celcuity? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celcuity and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit